C-Bridge Capital Leads $150M Round In Merged Chinese Drug Developer

For Digital Subscribers Only

C-Bridge Capital, a US$700 million-under-management healthcare private equity fund in China, has teamed up with Tianjin-based traditional Chinese medicine company Tasly Holding Group to invested US$150 million in a newly created Chinese drug developer resulted from a merger of two pharmaceutical firms.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

RELATED NEWS



LEAVE A REPLY